EQS-News

BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives - Seite 3

Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.

BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.

For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.

 

Contact Investor Relations

Martina Schuster
Investor Relations
Phone: [phone]
Email: [e-mail]

 

Contact Media

Dr. Stephanie Konle
PR & Corporate Communications
Phone: [phone]
Email: [e-mail]

 

 

 

---

29.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---

Language:	English
Company:	BRAIN Biotech AG
	Darmstädter Straße 34-36
	64673 Zwingenberg
	Germany
Phone:	+49 (0) 62 51 / 9331-0
Fax:	+49 (0) 62 51 / 9331-11
E-mail:	[e-mail]
Internet:	www.brain-biotech.com
ISIN:	DE0005203947
WKN:	520394
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1848949